Tivozanib (Fotivda®) for Relapse or Refractory Advanced Renal Cell Carcinoma

In an effort to promote higher quality patient care NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics. This PQI in Action is a follow up to the Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma PQI and explores how the medically integrated teams at American Oncology Network and Nebraska Cancer Specialists incorporate PQIs as part of their daily workflow. This article will discuss how utilizing the Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma PQI elevates patient care.